The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

Despite the impact of the pandemic on cancer care, Perjeta grew 17% to CHF 2.9 billion ($3.2 billion) in the first nine months of 2020, now just fractionally behind Herceptin which declined 31% to ...

Trastuzumab (Herceptin) was approved for the European market by Roche in August 2000 to treat ... A higher uptake for ...

Treatment with Herceptin (trastuzumab) can cut this risk by half. The pattern of breast cancer recurrence may also differ. Small tumors are also more likely to have a metastatic recurrence (in ...